Analyst Consensus ?
ConsensusHold28 ratings
Bullish1242.9%
Neutral1657.1%
Bearish00.0%
Invesco Ltd. · IVZ · FY2025 Q3 · Calendar Q4 2025
Invesco: Record AUM and inflows, with QQQ and platform milestones ahead
The supplied analysis supports a constructive but conditional view of Invesco's operating trajectory: strong ETF, fixed-income, and private-market demand, combined with balance-sheet actions, supports the growth case, while outflows, credit sensitivity, and execution or regulatory risks limit confidence.
Reported Before market openNYSEFinancial Services
$13.59B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.61
Consensus $0.45
EPS surprise
+36.1%
Reported versus consensus
Reported revenue
$1.19B
Consensus $1.18B
Revenue surprise
+0.9%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+2.1%
Event window
SPY move
+0.3%
Same window
Abnormal move
+1.9%
Stock minus SPY
Volume
1.9×
Versus trailing sessions
Subsequent drift
+1.1%
Up to 20 sessions
IVZSPY benchmark
Ask FN2 about IVZ FY2025 Q3
Transcript, numbers and history already loaded
Why did IVZ rise 2.1% after beating EPS estimates in FY2025 Q3?What changed in IVZ's guidance and outlook in FY2025 Q3?Give me the bull and bear case for IVZ after FY2025 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, Invesco's AUM and net long-term inflows increased to new reported records, while the current analysis added progress on the QQQ fee restructuring, planned asset sales, and continued Alpha platform execution. The risk profile still includes outflows and platform or regulatory timing.
Guidance delta
No formal guidance was provided in the supplied transcript analysis.
Key takeaways
- Record AUM and the strongest net long-term inflow quarter since 2021 were central positives in the supplied analysis.
- ETF, fixed-income, and private-market demand remained key growth drivers.
- Management emphasized balance-sheet deleveraging, capital returns, and operating leverage.
- The QQQ fee restructuring and hybrid Alpha platform remain important execution milestones.
- Fundamental-equity outflows, credit-market sensitivity, and regulatory timing remain counterweights.
Management priorities
- Complete the hybrid Alpha platform implementation by the end of 2026.
- Launch additional active ETFs and broaden the active-ETF lineup globally.
- Close the Intelliflo and India transactions and use proceeds for deleveraging and growth investments.
- Finalize the QQQ ETF fee change after shareholder approval.
- Maintain a 60% capital-return payout ratio while targeting further operating leverage.
Follow IVZ with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$30.66Current
$17Low
$28.79Average
$39High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 4, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Sep 25, 2026 |
| Evercore ISI Group | In Line | In Line | Maintain | Sep 9, 2026 |
| TD Cowen | Buy | Buy | Maintain | Aug 13, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Jul 29, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Jul 29, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 29, 2026 |
| Goldman Sachs | Neutral | Neutral | Maintain | Apr 29, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Apr 10, 2026 |
| Argus Research | Buy | Buy | Maintain | Jan 28, 2026 |
| Deutsche Bank | Buy | Hold | Upgrade | Dec 17, 2025 |
| B of A Securities | Neutral | Neutral | Maintain | Oct 2, 2025 |
| Citigroup | Neutral | Neutral | Maintain | Sep 29, 2025 |
| Wells Fargo | Equal Weight | Underweight | Upgrade | Jul 11, 2025 |
| UBS | Neutral | Neutral | Maintain | Feb 3, 2025 |
| Keefe, Bruyette & Woods | Market Perform | Market Perform | Maintain | Jan 29, 2025 |
| Credit Suisse | Neutral | Underperform | Upgrade | Mar 29, 2023 |
| Jefferies | Hold | Buy | Downgrade | Jun 7, 2019 |
| Keefe Bruyette & Woods | Market Perform | Outperform | Downgrade | Jul 13, 2018 |
| Argus | Buy | Buy | Maintain | May 5, 2018 |
| Bank of America | Neutral | Buy | Downgrade | Jan 8, 2018 |
| Keefe, Bruyette& Woods | Perform | Outperform | Downgrade | Dec 12, 2016 |
| Susquehanna | Positive | Positive | Maintain | Sep 3, 2015 |
| PiperJaffray | Overweight | Overweight | Maintain | Jun 3, 2015 |
| Sterne Agee | Buy | Neutral | Upgrade | Jan 7, 2015 |
| Evercore Partners | Equal Weight | Equal Weight | Maintain | Jul 10, 2013 |
| Nomura | Buy | Buy | Maintain | May 1, 2013 |
| Stifel Nicolaus | Buy | Buy | Maintain | Feb 1, 2013 |
| Stifel | Buy | Buy | Maintain | Feb 1, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $30.66. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Morgan Stanley | Michael Cyprys | $31 | $30.68 | +1.1% | Sep 25, 2026 |
| RBC Capital | Analyst unavailable | $39 | $32.02 | +27.2% | Aug 13, 2026 |
| Evercore ISI | Analyst unavailable | $35 | $32.05 | +14.2% | Aug 10, 2026 |
| Barclays | Analyst unavailable | $32 | $29.43 | +4.4% | Jul 29, 2026 |
| Barclays | Analyst unavailable | $31 | $28.4 | +1.1% | Jul 14, 2026 |
| Evercore ISI | Analyst unavailable | $32 | $29.08 | +4.4% | Jul 10, 2026 |
| Evercore ISI | Analyst unavailable | $31 | $27.79 | +1.1% | Jun 8, 2026 |
| Goldman Sachs | Alexander Blostein | $30 | $25.88 | -2.2% | Apr 29, 2026 |
| Barclays | Analyst unavailable | $26 | $25.88 | -15.2% | Apr 29, 2026 |
| RBC Capital | Kenneth Lee | $31 | $24.95 | +1.1% | Apr 21, 2026 |
| Evercore ISI | Analyst unavailable | $27 | $23.63 | -11.9% | Apr 10, 2026 |
| BMO Capital | Analyst unavailable | $28 | $23.63 | -8.7% | Apr 10, 2026 |
| RBC Capital | Kenneth Lee | $33 | $27.76 | +7.6% | Jan 28, 2026 |
| Cowen & Co. | Analyst unavailable | $34.5 | $27.28 | +12.5% | Jan 28, 2026 |
| Argus Research | Stephen Biggar | $31 | $27.26 | +1.1% | Jan 28, 2026 |
| Goldman Sachs | Analyst unavailable | $29.5 | $27.16 | -3.8% | Jan 28, 2026 |
| Barclays | Analyst unavailable | $29 | $27.16 | -5.4% | Jan 28, 2026 |
| Morgan Stanley | Analyst unavailable | $29 | $28.4 | -5.4% | Jan 26, 2026 |
| RBC Capital | Kenneth Lee | $35 | $28.95 | +14.2% | Jan 21, 2026 |
| Goldman Sachs | Alexander Blostein | $28.75 | $28.25 | -6.2% | Jan 15, 2026 |
| Barclays | Benjamin Budish | $30 | $28.25 | -2.2% | Jan 15, 2026 |
| Goldman Sachs | Alexander Blostein | $28.25 | $28.16 | -7.9% | Jan 6, 2026 |
| Morgan Stanley | Analyst unavailable | $28 | $26.82 | -8.7% | Dec 17, 2025 |
| Deutsche Bank | Analyst unavailable | $31 | $26.03 | +1.1% | Dec 17, 2025 |
| Barclays | Benjamin Budish | $28 | $26.99 | -8.7% | Dec 12, 2025 |
| BMO Capital | Analyst unavailable | $30 | $26.54 | -2.2% | Dec 10, 2025 |
| Goldman Sachs | Analyst unavailable | $25.5 | $23.81 | -16.8% | Nov 25, 2025 |
| Fundamental Research | Analyst unavailable | $27 | $23.66 | -11.9% | Oct 31, 2025 |
| RBC Capital | Kenneth Lee | $25 | $24.02 | -18.5% | Oct 30, 2025 |
| Goldman Sachs | Analyst unavailable | $26.5 | $24.35 | -13.6% | Oct 29, 2025 |
| Barclays | Analyst unavailable | $24 | $22.84 | -21.7% | Oct 21, 2025 |
| Morgan Stanley | Analyst unavailable | $26 | $23.98 | -15.2% | Oct 6, 2025 |
| Evercore ISI | Glenn Schorr | $24 | $21.99 | -21.7% | Sep 5, 2025 |
| Wells Fargo | Michael Brown | $18 | $17.43 | -41.3% | Jul 11, 2025 |
| Barclays | Benjamin Budish | $19 | $18.04 | -38.0% | Oct 23, 2024 |
| Wells Fargo | Michael Brown | $16 | $15.8 | -47.8% | Sep 11, 2024 |
| RBC Capital | Kenneth Lee | $16 | $14.52 | -47.8% | Apr 25, 2024 |
| Deutsche Bank | Brian Bedell | $17 | $16.53 | -44.6% | Apr 5, 2024 |
| Morgan Stanley | Analyst unavailable | $23 | $18.96 | -25.0% | Apr 27, 2022 |
| Deutsche Bank | Brian Bedell | $24 | $19.03 | -21.7% | Apr 27, 2022 |
| Morgan Stanley | Analyst unavailable | $25 | $20.39 | -18.5% | Apr 25, 2022 |
| RBC Capital | Kenneth Lee | $23 | $21.41 | -25.0% | Jan 24, 2022 |
| Barclays | Jeremy Campbell | $25 | $26.29 | -18.5% | Apr 30, 2021 |
| Argus Research | Stephen Biggar | $33 | $26.51 | +7.6% | Apr 28, 2021 |
| Wells Fargo | Christopher Harris | $25 | $25.23 | -18.5% | Apr 13, 2021 |
Track every rating change on IVZ the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationInvesco Ltd. engages in the investment management business. Its products include mutual funds, unit trusts, exchange-traded funds, closed-end funds, and retirement plans. The company was founded in December 1935 and is headquartered in Atlanta, GA.
Historical context
All IVZ earningsFinancial Services peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| FDS FactSet Research Systems Inc. | FY2026 Q4 · Calendar Q3 2026 | +3.9% | +3.8% | FactSet reports record FY26 results as AI and MCP adoption accelerate |
| PUK Prudential plc | FY2026 Q2 · Calendar Q3 2026 | -40.9% | -0.5% | Prudential sustains growth and capital returns focus in H1 2026 |
| CM Canadian Imperial Bank of Commerce | FY2026 Q3 · Calendar Q3 2026 | +8.9% | -2.8% | CIBC Q3: Broad growth, resilient credit and expanded AI rollout |
| TD The Toronto-Dominion Bank | FY2026 Q3 · Calendar Q3 2026 | +13.8% | +1.4% | TD emphasizes growth investments alongside disciplined capital management |
| RY Royal Bank of Canada | FY2026 Q3 · Calendar Q3 2026 | +6.2% | -1.3% | RBC reports record Q3 earnings while investing for growth |
| AFRM Affirm Holdings, Inc. | FY2026 Q4 · Calendar Q3 2026 | +1230.3% | +0.3% | Affirm's most profitable quarter shifts focus to product execution |
Latest beats and misses
Who reports nextBeat on EPS
- ACNFY2026 Q4 · October 1, 2026+3.5% EPS+15.8% move
- MKCFY2026 Q3 · October 1, 2026+13.9% EPS-4.9% move
- NKEFY2027 Q1 · October 1, 2026+10.0% EPS-0.7% move
- CAGFY2027 Q1 · September 30, 2026+44.4% EPS-4.9% move
- FDSFY2026 Q4 · September 30, 2026+3.9% EPS+3.8% move
- JBLFY2026 Q4 · September 30, 2026+8.1% EPS-10.0% move
Get the IVZ recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-10-04T16:50:42.882466+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-04T16:50:42.879102+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-04. For educational purposes only; not investment advice.